As CD8+ TILs and TMB are both well-established prognostic and predictive markers for cancer immunotherapy using ICIs, such as anti-CTLA4, anti-PD-1, and anti-PD-L1 monoclonal antibodies,36–39 whether patients with a relatively low proportion of DP Temra in peripheral blood indeed respond better to checkpoint blockade therapies will be interesting to explore. The gene discussed is PDCD1; the disease is cancer.